Hap Trading, LLC Prothena Corp Public LTD CO Transaction History

Hap Trading, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $733,469 - $1.19 Million	22,701 New	22,701 $825 Million
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $4.06 Million - $5.73 Million	-458,644 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$10.32 - $14.49 $2.03 Million - $2.84 Million	-196,303 Reduced 29.97%	458,644 $5.56 Million
Q4 2018 Feb 12, 2019	BUY	$8.73 - $13.74 $2.61 Million - $4.11 Million	298,892 Added 83.95%	654,947 $6.75 Million
Q3 2018 Nov 09, 2018	BUY	$12.7 - $15.79 $2.88 Million - $3.59 Million	227,125 Added 176.16%	356,055 $4.66 Million
Q2 2018 Aug 13, 2018	BUY	$10.99 - $44.21 $924,280 - $3.72 Million	84,102 Added 187.61%	128,930 $1.88 Million
Q1 2018 May 11, 2018	BUY	$27.95 - $45.04 $1.25 Million - $2.02 Million	44,828 New	44,828 $1.65 Million

190

42.9M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $661M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.